
What happened
Boltz raised $110 million in a Series A led by Bessemer, with backers including Greycroft and Andreessen Horowitz, to expand its AI drug-discovery models.
Why it matters
The funding will let Boltz grow its headcount and buy more computing infrastructure, helping it keep pace with larger AI labs moving into biology research, the company said.
WHO IT HITSPharmaceutical research teams that screen hundreds of thousands of molecules per project may get faster, cheaper binding-affinity data from Boltz's models, potentially shortening early-stage drug discovery. The startup counts six of the world's 20 largest pharma companies as clients.
Summaries like this, every morning.
Boltz's raise comes as general-purpose AI labs have pushed into biology. Over the past year, Anthropic and OpenAI have each introduced models highly adapted to biology research tasks, and Boltz says the extra computing infrastructure from this round should help it keep up with them.
The startup's pitch rests on a narrower workflow: finding small molecule hits, the faint early clues that tell researchers where to focus. In an internal test across 10 challenging and therapeutically-relevant targets, BoltzMol-1 found hits for six of them. Boltz also offers BoltzProt-1, which generates tens of thousands of protein designs from that hit data and screens each one for drug potential. The company says its protein evaluation mechanism showed “higher success” than several competing models in internal tests.
Boltz sells access to its algorithms via an API billed by token usage, and customer token consumption has grown by a factor of 50 since the two models launched in June. That usage, plus six of the world's 20 largest pharma companies as clients, suggests the tools are finding paid use even before the next generation of models is ready. Boltz says those new algorithms are already in training and “showing substantial improvements” over its current models.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
At the Dell Technologies New York Symposium, Dell CTO John Roese said the moat in AI systems is not the tools…
IDC's Worldwide Future of Work Survey (May 2026) found the majority of "leaders" — organizations reporting 50%…

ABB and SynerLeap named Wasome winner of the ABB Startup Challenge China 2026, awarding a 200,000 CNY (about $…

Anthropic debuted on the Nasdaq Thursday, initially raising $81.3 billion at a price of $83 per share, then bo…

In its 2026 sustainability report, Meta said it is re-evaluating the 2030 timeframe for its net-zero goal, aft…

American Banker published exclusive research examining how JPMorgan's AI strategy is putting governance to the…
